The Hormones and Cancer group comprises two main arms of research. The first focus is in the genomics of pituitary tumours, in particular our current projects are uncovering new genes involved in familial predisposition to pituitary tumours, and also using genomics to determine new treatment targets for aggressive pituitary tumours.
Recently, we have developed a unifying gene panel to allow cost-effective genomic testing across other less well-studied cancer types. The second focus of research is examining the hormonal influence, in particular the effect of obesity, on cancer development and progression.
Gregory LC, Gevers EF, Baker J, Kasia T, Chong K, Josifova DJ, Caimari M, Bilan F, McCabe MJ, Dattani MT. Structural pituitary abnormalities associated with CHARGE syndrome. J Clin Endocrinol Metab. 2013; 98(4):E737-43.
Greenfield, JR and McCormack, AI. Medication to prevent breast cancer – too much to swallow? Med J Aust 2012; 196(5):314.
McCormack, AI et al. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 2011; 41(10):1133-48.
McCabe MJ et al. Septo-optic dysplasia and other midline defects: the role of transcription factors: HESX1 and beyond. Best Pract Res Clin Endocrinol Metab. 2011; 25(1):115-24.
McCabe MJ et al. Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. J Clin Endocrinol Metab. 2011; 96(10):E1709-18.
McCormack, AI et al. Low 06-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol 2009; 71(2): 226-33.
More Garvan Publications
In the News
What pituitary tumours may tell us about the biology of other cancers - Jul 27, 2012